CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target
Behl et al.
, CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target
, Science of The Total Environment, doi:10.1016/j.scitotenv.2021.152072 (Review)
Review of the cluster of differentiation 147 (CD147) transmembrane protein as an entry route for SARS-CoV-2, correlation with observed characteristics of COVID-19, and relevant potential therapeutics including azithromycin, melatonin, statins, beta adrenergic blockers, ivermectin, and meplazumab.
Behl et al., 1 Dec 2021, peer-reviewed, 9 authors.
Abstract: Science of the Total Environment 808 (2022) 152072
Contents lists available at ScienceDirect
Science of the Total Environment
journal homepage: www.elsevier.com/locate/scitotenv
CD147-spike protein interaction in COVID-19: Get the ball rolling with a
novel receptor and therapeutic target
Tapan Behl a, , Ishnoor Kaur a, Lotﬁ Aleya b, , Aayush Sehgal a, Sukhbir Singh a, Neelam Sharma a,
Saurabh Bhatia c, Ahmed Al-Harrasi c, Simona Bungau d,
Chitkara College of Pharmacy, Chitkara University, Punjab, India
Chrono-Environment Laboratory, UMR CNRS 6249, Bourgogne Franche-Comté University, France
Natural & Medical Sciences Research Centre, University of Nizwa, Nizwa, Oman
Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Romania
H I G H L I G H T S
G R A P H I C A L
A B S T R A C T
• Elaborating the severity of the COVID-19
pandemic and ACE-2-mediated entry of
• Examining the relationship between
malaria-causing Plasmodium falciparum
receptor, CD147, and SARS-CoV-2
• CD147, evidently serving as an alternative
entry receptor for viral entry
• The catch and clump hypothesis
• CD147 as a possible therapeutic target for
A R T I C L E
I N F O
Received 10 August 2021
Received in revised form 26 November 2021
Accepted 26 November 2021
Available online 1 December 2021
Editor: Damia Barcelo
Catch and clump
A B S T R A C T
The combat against the Corona virus disease of 2019 (COVID-19), has created a chaos among the healthcare institutions and researchers, in turn accelerating the dire need to curtail the infection spread. The already established
entry mechanism, via ACE2 has not yet successfully aided in the development of a suitable and reliable therapy. Taking
in account the constant progression and deterioration of the cases worldwide, a different perspective and mechanistic
approach is required, which has thrown light onto the cluster of differentiation 147 (CD147) transmembrane protein,
as a novel route for SARS-CoV-2 entry. Despite lesser afﬁnity towards COVID-19 virus, as compared to ACE2, this receptor provides a suitable justiﬁcation behind elevated blood glucose levels in infected patients, retarded COVID-19
risk in women, enhanced susceptibility in geriatrics, greater infection susceptibility of T cells, infection prevalence
in non-susceptible human cardiac pericytes and so on. The manuscript invokes the title role and distribution of
CD147 in COVID-19 as an entry receptor and mediator of endocytosis-promoted entry of the virus, along with the
“catch and clump” hypothesis, thereby presenting its Fundamental signiﬁcance as a therapeutic target for potential
candidates, such as Azithromycin, melatonin, statins, beta adrenergic blockers, ivermectin, Meplazumab etc. Thus,
the authors provide a comprehensive review of a different perspective in COVID-19 infection, aiming to aid the researchers and virologists in considering all aspects of viral entry, in order to develop a sustainable and potential
cure for the 2019 COVID-19 disease.
⁎ Corresponding authors at: Chitkara College of Pharmacy, Chitkara University, Punjab, India.
⁎⁎ Co-corresponding author.
E-mail addresses: email@example.com (T. Behl), firstname.lastname@example.org (S. Bungau).
0048-9697/© 2021 Elsevier B.V. All rights reserved.
T. Behl et al.
Science of the Total..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.